Marc Goodman
Stock Analyst at Leerink Partners
(2.91)
# 1,607
Out of 4,944 analysts
92
Total ratings
56.16%
Success rate
26.81%
Average return
Main Sectors:
Stocks Rated by Marc Goodman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHVN Biohaven | Maintains: Outperform | $60 → $50 | $14.39 | +247.46% | 7 | Aug 12, 2025 | |
| AMLX Amylyx Pharmaceuticals | Upgrades: Outperform | $4 → $10 | $8.30 | +20.48% | 5 | May 7, 2025 | |
| OPT Opthea | Downgrades: Market Perform | $12 → $1 | $3.41 | -70.67% | 2 | Mar 25, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $110 → $150 | $109.39 | +37.12% | 7 | Feb 10, 2025 | |
| RLMD Relmada Therapeutics | Downgrades: Market Perform | $10 → $1 | $0.57 | +75.99% | 3 | Dec 4, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $32 | $39.36 | -18.70% | 1 | Apr 15, 2024 | |
| BLTE Belite Bio | Initiates: Outperform | $25 | $72.23 | -65.39% | 1 | Jul 26, 2023 | |
| DNLI Denali Therapeutics | Initiates: Outperform | $50 | $14.81 | +237.61% | 1 | Jan 30, 2023 | |
| EOLS Evolus | Maintains: Outperform | $18 → $20 | $6.51 | +207.22% | 3 | Jan 19, 2023 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $100 → $115 | $131.62 | -12.63% | 4 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $310 | $135.19 | +129.31% | 11 | Oct 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $12 | $13.77 | -12.85% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $46 | $37.67 | +22.11% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $21 | $25.13 | -16.43% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $210 | $117.12 | +79.30% | 5 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $2.20 | +354.55% | 2 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $24 → $27 | $28.63 | -5.69% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $15 | $5.37 | +179.33% | 2 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $270 | $532.71 | -49.32% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $79 → $96 | $201.47 | -52.35% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $47.85 | - | 2 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $67 | $82.71 | -18.99% | 3 | Oct 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $98 | $23.66 | +314.20% | 7 | Oct 5, 2017 |
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $60 → $50
Current: $14.39
Upside: +247.46%
Amylyx Pharmaceuticals
May 7, 2025
Upgrades: Outperform
Price Target: $4 → $10
Current: $8.30
Upside: +20.48%
Opthea
Mar 25, 2025
Downgrades: Market Perform
Price Target: $12 → $1
Current: $3.41
Upside: -70.67%
Axsome Therapeutics
Feb 10, 2025
Maintains: Outperform
Price Target: $110 → $150
Current: $109.39
Upside: +37.12%
Relmada Therapeutics
Dec 4, 2024
Downgrades: Market Perform
Price Target: $10 → $1
Current: $0.57
Upside: +75.99%
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: $32
Current: $39.36
Upside: -18.70%
Belite Bio
Jul 26, 2023
Initiates: Outperform
Price Target: $25
Current: $72.23
Upside: -65.39%
Denali Therapeutics
Jan 30, 2023
Initiates: Outperform
Price Target: $50
Current: $14.81
Upside: +237.61%
Evolus
Jan 19, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $6.51
Upside: +207.22%
Neurocrine Biosciences
Nov 2, 2022
Maintains: Market Perform
Price Target: $100 → $115
Current: $131.62
Upside: -12.63%
Oct 26, 2022
Maintains: Outperform
Price Target: $270 → $310
Current: $135.19
Upside: +129.31%
Aug 11, 2022
Maintains: Outperform
Price Target: $6 → $12
Current: $13.77
Upside: -12.85%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $46
Current: $37.67
Upside: +22.11%
Aug 9, 2022
Maintains: Outperform
Price Target: $27 → $21
Current: $25.13
Upside: -16.43%
Aug 4, 2022
Maintains: Outperform
Price Target: $200 → $210
Current: $117.12
Upside: +79.30%
Jul 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $2.20
Upside: +354.55%
Apr 28, 2022
Maintains: Market Perform
Price Target: $24 → $27
Current: $28.63
Upside: -5.69%
Dec 21, 2021
Maintains: Outperform
Price Target: $24 → $15
Current: $5.37
Upside: +179.33%
Mar 13, 2020
Maintains: Buy
Price Target: $300 → $270
Current: $532.71
Upside: -49.32%
Nov 19, 2019
Maintains: Buy
Price Target: $79 → $96
Current: $201.47
Upside: -52.35%
May 21, 2018
Downgrades: Neutral
Price Target: n/a
Current: $47.85
Upside: -
Oct 30, 2017
Maintains: Buy
Price Target: $72 → $67
Current: $82.71
Upside: -18.99%
Oct 5, 2017
Maintains: Buy
Price Target: $84 → $98
Current: $23.66
Upside: +314.20%